Sanjiv Patel Relay Therapeutics, Inc. (RLAY) insider trading activity

Sanjiv Patel is President and CEO of Relay Therapeutics, Inc.. Currently has a direct ownership of 703,215 shares of RLAY, which is worth approximately $4.66 Million. The most recent transaction as insider was on Nov 03, 2025, when has been sold 62,073 shares (Common Stock) at a price of $7.0 per share, resulting in proceeds of $434,511. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 703K

8.11% 3M change

8.21% 12M change

Total Value Held $4.66 Million

Sanjiv Patel Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 03 2025	SELL Open market or private sale	$434,511 $7.0 p/Share	62,073 Reduced 8.11%	703,215 Common Stock
Jul 09 2025	SELL Open market or private sale	$219,123 $3.57 p/Share	61,379 Reduced 7.42%	765,288 Common Stock
Jun 30 2025	BUY Grant, award, or other acquisition	$14,700 $2.94 p/Share	5,000 Added 0.6%	826,667 Common Stock
Apr 23 2025	SELL Open market or private sale	$182,423 $2.97 p/Share	61,422 Reduced 6.96%	821,667 Common Stock
Feb 13 2025	SELL Open market or private sale	$278,698 $3.7 p/Share	75,324 Reduced 7.86%	883,089 Common Stock
Feb 11 2025	SELL Open market or private sale	$539,700 $3.85 p/Share	140,182 Reduced 18.3%	625,948 Common Stock
Feb 11 2025	BUY Grant, award, or other acquisition	-	332,465 Added 25.75%	958,413 Common Stock

Jul 26 2024	SELL Open market or private sale	$332,923 $9.07 p/Share	36,706 Reduced 4.57%	766,130 Common Stock
Jul 26 2024	BUY Exercise of conversion of derivative security	$184,998 $5.04 p/Share	36,706 Added 4.37%	802,836 Common Stock
Jul 25 2024	SELL Open market or private sale	$458,000 $9.16 p/Share	50,000 Reduced 6.13%	766,130 Common Stock
Jul 25 2024	BUY Exercise of conversion of derivative security	$252,000 $5.04 p/Share	50,000 Added 5.77%	816,130 Common Stock
Jun 30 2024	BUY Grant, award, or other acquisition	$11,678 $5.54 p/Share	2,108 Added 0.27%	766,130 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	762,360 Added 49.95%	764,022 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$17,750 $10.68 p/Share	1,662 Added 50.0%	1,662 Common Stock
Feb 09 2023	SELL Open market or private sale	$287,700 $20.55 p/Share	14,000 Reduced 100.0%	0 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	$70,560 $5.04 p/Share	14,000 Added 50.0%	14,000 Common Stock
Feb 08 2023	SELL Open market or private sale	$293,720 $20.98 p/Share	14,000 Reduced 100.0%	0 Common Stock
Feb 08 2023	BUY Exercise of conversion of derivative security	$70,560 $5.04 p/Share	14,000 Added 50.0%	14,000 Common Stock
Feb 07 2023	SELL Open market or private sale	$300,300 $21.45 p/Share	14,000 Reduced 100.0%	0 Common Stock
Feb 07 2023	BUY Exercise of conversion of derivative security	$70,560 $5.04 p/Share	14,000 Added 50.0%	14,000 Common Stock
Jan 19 2023	SELL Open market or private sale	$560,560 $20.02 p/Share	28,000 Reduced 9.91%	254,554 Common Stock
Jan 19 2023	BUY Exercise of conversion of derivative security	$141,120 $5.04 p/Share	28,000 Added 9.02%	282,554 Common Stock
Jan 18 2023	SELL Open market or private sale	$584,360 $20.87 p/Share	28,000 Reduced 9.91%	254,554 Common Stock
Jan 18 2023	BUY Exercise of conversion of derivative security	$141,120 $5.04 p/Share	28,000 Added 9.02%	282,554 Common Stock
Jan 17 2023	SELL Open market or private sale	$566,440 $20.23 p/Share	28,000 Reduced 9.91%	254,554 Common Stock

Also insider at

PRTA

PROTHENA CORP PUBLIC LTD CO Healthcare

Sanjiv Patel

President and CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLAY shares.

Notify only if

Value

Insider Trading

Get notified when an Relay Therapeutics, Inc. insider buys or sells RLAY shares.

Notify only if

Operation

Value

Type

News

Receive news related to Relay Therapeutics, Inc.

Track Activities on RLAY

Account